Mounjaro (Tirzepatide)
Brand Names: Mounjaro
Methodology & AI Transparency ⓘ
Mounjaro (Tirzepatide) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Mounjaro is a prescription brand-name glucose-dependent insulinotropic polypeptide receptor agonist product delivering active moiety Tirzepatide (cross-referenced at /meds/tirzepatide), registered by A-S Medication Solutions under NDC 50090-8021, 0002-1484.
- 2 Real-world patient consensus: Mounjaro links directly to generic Tirzepatide (/meds/tirzepatide) under FDA SPL 2026-07-29 (NDC 50090-8021).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $640.00 cash mean against $1696.00 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Mounjaro (Tirzepatide): nausea (12.6%), diarrhea (9.9%), vomiting (6.2%).
Ask our AI Specialists anything about Mounjaro (Tirzepatide)
Mounjaro (Tirzepatide) Mechanism, CYP450 Pathways & DailyMed Monograph
Mounjaro is a prescription brand-name glucose-dependent insulinotropic polypeptide receptor agonist product delivering active moiety Tirzepatide (cross-referenced at /meds/tirzepatide), registered by A-S Medication Solutions under NDC 50090-8021, 0002-1484. Updated in FDA DailyMed SPL on 2026-07-29, this branded presentation (7.5 mg/.5mL Injection, Solution; 10 mg/.5mL Injection, Solution) supports 1 Indications and usage mounjaro: ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults.
Pharmacologically, Mounjaro derives its clinical activity from Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor agonist molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (7.5 mg/.5mL Injection, Solution; 10 mg/.5mL Injection, Solution; registered by A-S Medication Solutions) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Tirzepatide (CMS NADAC $523.0483/unit vs. $1696.00 retail).
With Approximately 3–12 hours terminal plasma half-life for Mounjaro (Tirzepatide) residence kinetics and Complete (~100%) parenteral systemic delivery for Mounjaro (Tirzepatide) (7.5 mg/.5mL Injection, Solution) bioavailability, Mounjaro (Tirzepatide) undergoes phase i/ii hepatic conjugation of mounjaro (tirzepatide) coupled with glomerular and tubular renal excretion and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after mounjaro (tirzepatide) administration.
Standard adult regimens span 7.5 mg/.5mL Injection, Solution, 10 mg/.5mL Injection, Solution, 5 mg/.5mL Injection, Solution, 2.5 mg/.5mL Injection, Solution, 25 mg/mL Injection, Solution. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to tirzepatide or mounjaro (tirzepatide) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-29 mounjaro (tirzepatide) spl, while community micro-logs most frequently note nausea (12.6% of reports), diarrhea (9.9% of reports), headache (7.1% of reports).
Avoid overlapping glucose-dependent insulinotropic polypeptide receptor agonist prescriptions alongside Mounjaro (Tirzepatide) to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Mounjaro (Tirzepatide) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Tirzepatide or Mounjaro (Tirzepatide) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-29 Mounjaro (Tirzepatide) SPL
Logged Side-Effect Incidence (9 Reports)
Mounjaro (Tirzepatide) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mounjaro (Tirzepatide))
Human clinical trial evidence for Mounjaro (Tirzepatide) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Mounjaro (Tirzepatide) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $523.0483/unit (~$15691.45/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Mounjaro (Tirzepatide) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mounjaro (Tirzepatide) RxNorm Concept ID | 2601767 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $523.0483 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Mounjaro (Tirzepatide) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Mounjaro (Tirzepatide) (glucose-dependent insulinotropic polypeptide receptor agonist) monograph synthesizing RxNorm 2601767, openFDA FAERS signals, and $640.00–$1696.00 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Mounjaro (Tirzepatide) community threads and patient logs by age, biological sex, dosage, and treatment duration.